A Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Infusion of hUC-MSCs in Patients With AIS
Conditions
- Acute Ischemic Stroke AIS
Interventions
- DRUG: hUC-MSCs treatment (high dose)
- DRUG: hUC-MSCs treatment (low dose)
- DRUG: Placebo
Sponsor
Shenzhen Wingor Biotechnology Co., Ltd.
Collaborators